gaseou
nitric
oxid
gno
approv
vasodil
drug
inhal
maximum
dose
ppm
gno
shown
vitro
eff
ctive
antibacteri
agent
ppm
nodonor
compound
shown
inhibit
varieti
virus
vari
stage
replic
research
done
order
determin
whether
gno
ppm
possess
antivir
effect
influenza
virus
three
strain
influenza
b
expos
gno
min
infect
mdck
cell
search
possibl
mechan
antivir
action
neuramin
idas
na
inhibit
assay
expos
gno
perf
orm
result
show
virion
expos
gno
prior
infect
complet
inhibit
infect
achiev
three
strain
post
infect
exposur
influenza
gno
result
inhibit
infect
test
show
elimin
ph
effect
expos
dri
viru
gno
inhibit
found
h
exposur
na
activ
whole
dri
viru
found
inhibit
gno
result
suggest
ppm
gno
time
depend
antivir
effect
influenza
strain
virus
variou
stage
cellular
infect
due
concomit
chang
ph
surround
milieu
viral
na
inhibit
gno
shown
may
responsibl
e
antivir
effect
centuri
influenza
affect
human
health
season
recur
pandem
despit
signific
reduct
diseas
burden
vaccin
effort
circul
season
influenza
b
virus
caus
excess
morbid
mortal
particularli
patient
preexist
pulmonari
condit
report
season
flu
responsib
le
death
hospit
cost
billion
year
unit
state
two
subtyp
influenza
viru
circul
within
human
popul
influenza
virus
broad
host
rang
thu
differ
influenza
b
limit
host
rang
infect
human
seal
host
influenza
b
virus
caus
signific
diseas
predomin
circul
strain
influenza
viru
approximat
eli
one
everi
case
influenza
b
virus
present
two
type
surfac
protein
hemagglutinin
ha
neuraminidas
na
matrix
protein
protonselect
ion
channel
protein
integr
viral
envelop
influenza
b
virus
harbor
interest
genet
differ
influenza
includ
addit
encod
protein
may
differ
characterist
ic
protein
specif
translat
stopstart
translat
mechan
differ
influenza
virus
translat
splice
transcrip
pandem
occur
anim
virus
acquir
mutat
directli
reassortm
nt
human
virus
adapt
replic
transmi
sion
human
host
recent
world
experienc
global
lifethreatenin
g
phase
pandem
caus
novel
swine
origin
viru
past
pandem
influenza
virus
need
month
spread
allow
suffici
time
develop
new
vaccin
experienc
new
viru
spread
worldwid
e
less
week
virul
higher
mortal
rate
prior
avail
vaccin
would
catastroph
rapid
spread
viral
infect
recent
experienc
grave
concern
developmen
window
manufactur
effect
vaccin
may
suffici
order
provid
widespread
global
immun
thu
viral
infect
control
method
mainli
depend
antivir
agent
two
class
antivir
medic
current
use
treat
prevent
influenza
infect
adamantan
neuraminidas
inhibitor
adamanti
ne
deriv
amantadin
rimantadin
act
protein
influenza
effect
influenza
b
developmen
wide
spread
amantadin
resist
strain
season
limit
util
fortun
recent
pandem
swine
origin
viru
influenza
b
virus
still
suscept
two
na
inhibit
drug
zanamivi
r
inhal
oseltamivir
oral
zanamavir
relenza
oseltamivir
tamiflu
licens
worldwid
e
treatment
prevent
influenza
oseltami
virresist
virus
recent
increas
circul
especi
among
viru
new
antivir
develop
last
year
given
rapidli
evolv
natur
antivir
resist
option
warrant
explor
nitric
oxid
free
radic
ga
molecul
play
major
role
innat
immun
mammalian
host
defens
infect
modul
wound
heal
vasodil
neurotransmiss
angiogenesi
free
deriv
donat
compound
report
exhibit
antimicrobi
activ
vitro
vivo
anim
studi
literatur
support
deriv
inhibitori
effect
varieti
viral
infect
inhibitori
effect
shown
mark
ifnmedi
inhibit
manifest
activ
macrophag
also
shown
correl
snitrosyl
ation
viral
protein
reductas
proteas
review
convers
appear
despit
seemingli
benefici
role
viral
infect
product
respons
viral
insult
may
lead
detriment
effect
host
particularli
influenza
infect
antivir
effect
previous
shown
use
variou
donor
compound
report
inhibit
replicatio
n
dna
rna
virus
coxsacki
viru
coronaviru
dengu
viru
rimmelzwaan
et
al
shown
replic
influenza
virus
mdck
cell
sever
impair
donor
snitronacetylpenici
llamin
snap
show
antivir
effect
correl
inhibit
viral
rna
synthesi
indic
may
interfer
earli
stage
replicatio
n
still
mechan
influenza
inhibit
complet
understood
gaseou
form
gno
approv
inhal
drug
therapeut
treatment
pulmonari
hypertens
newborn
concentratio
n
part
per
million
ppm
shown
gno
dose
lower
ppm
antibacteri
shown
effect
antibacteri
concentratio
n
gno
ppm
purport
inhal
gno
may
use
antimicrobi
treatment
pulmonari
infect
knowl
ge
report
evalu
highest
approv
level
ppm
higher
antibacteri
dose
gno
identifi
antivir
potenti
influenza
virus
studi
evalu
effect
gno
three
repres
influenza
virus
infect
cell
cellfre
vitro
model
util
previous
valid
gno
exposur
system
chose
use
strain
repres
season
influenza
subtyp
influenza
influenza
b
viru
order
elucid
potenti
antivir
mechan
action
evalu
effect
gno
inhibit
surfac
protein
na
viru
madindarbi
canin
kidney
epitheli
mdck
cell
atcc
obtain
american
type
cultur
collect
maintain
ed
dulbecco
minim
essenti
medium
dmem
supplement
fetal
bovin
serum
fb
incub
humidifi
atmospher
co
without
antibiot
antimycot
agent
mdck
cell
grown
monolay
cell
cultur
flask
passag
use
experim
nt
viral
strain
obtain
laboratori
stock
british
columbia
center
diseas
control
stock
influenza
virus
influenza
b
viru
bhong
grown
mdck
h
medium
contain
lgml
modifi
trypsin
treat
tpck
without
serum
stock
virus
prepar
clarifi
cellfre
supernat
ant
viru
concentr
ation
stock
determin
standard
plaqu
assay
mdck
cell
viru
titer
stock
influenza
b
plaqu
form
unit
pfu
ml
respect
design
valid
continu
horizont
flow
gno
deliveri
devic
use
studi
describ
detail
elsewher
brief
devic
consist
two
cylindr
plexigla
exposur
chamber
separ
ga
entri
port
common
exit
port
chamber
surround
airtight
plexigla
jacket
creat
thermal
isol
environm
ent
jacket
enclos
electr
heater
unit
control
intern
thermost
invensi
applianc
control
carol
stream
illinoi
usa
provid
stabl
temperatur
insid
chamber
independ
line
two
exposur
chamber
provid
sampl
ga
mixtur
nono
electrochem
analyz
aeronox
pulmonox
medic
inc
tofield
ab
canada
detect
exact
composit
gase
mixtur
gase
suppli
pressur
cylind
constant
pressur
pound
per
squar
inch
includ
part
per
million
ppm
dilut
n
airga
chicago
usa
medic
air
praxair
mississauga
canada
gase
mix
togeth
predetermin
concentr
ation
use
dilut
manifold
digit
mass
flow
meter
tsi
inc
shoreview
mn
usa
ga
mixtur
ppm
deliv
exposur
chamber
rate
lmin
rel
humid
temperat
ure
approxim
appropri
experim
nt
two
independ
humidifi
fisher
paykel
healthcar
ca
usa
control
chamber
contain
air
flow
lmin
confluent
monolay
mdck
cell
plate
wash
phosphat
e
buffer
salin
pb
infect
influenza
viru
pfuwel
plate
continu
shaken
shaker
min
viru
adsorptio
n
inoculum
remov
replac
ml
salin
fb
per
well
infect
plate
treat
either
ppm
gno
treatment
air
control
h
time
point
salin
remov
replac
mlwell
overlay
medium
consist
dmem
supplem
ent
agaros
lgml
tpcktrypsin
day
incub
infect
cell
fix
buffer
formalin
stain
crystal
violet
number
plaqu
count
insur
effect
cell
noninfect
cell
viabil
exposur
confirm
virucid
cellfre
effect
gaseou
nitric
oxid
pfuml
indic
viru
treat
ppm
gno
salin
fb
min
end
time
point
viru
infect
measur
use
plaqu
reduct
assay
confluent
mdck
cell
grown
cultur
plate
infect
viru
control
treat
sampl
give
plaqu
per
well
optim
visual
plate
incub
h
follow
h
absorpt
viru
inoculum
remov
cell
cultur
day
mlwell
overlay
medium
follow
fixat
stain
describ
nitrit
ph
content
short
halflif
vivo
second
therefor
level
stabl
metabolit
nitrit
nitrat
use
indirect
measurem
nt
experi
nitrit
concentr
end
treatment
measur
use
griess
reagent
sampl
l
salin
taken
treatment
control
plate
one
well
test
nitrit
concentr
ph
elimin
effect
ph
viral
inhibit
anoth
experi
done
use
dri
viru
aliquot
viru
l
approximat
eli
pfu
dilut
salin
plu
fb
spot
onto
steril
glass
slide
mm
let
dri
air
insid
biosafeti
cabinet
min
glass
slide
treat
flow
lm
ppm
gno
min
control
treat
lm
air
flow
sampl
reconstitut
ml
pb
viru
infect
measur
use
plaqu
reduct
assay
outlin
sinc
nitrit
low
ph
found
treat
sampl
individu
effect
test
pfuml
final
concentratio
n
ad
ml
salin
b
salin
mm
nitrit
c
salin
ad
citric
acid
reduc
ph
min
viru
infectivit
measur
use
plaqu
reduct
assay
explain
order
test
possibl
mechan
viral
inhibit
na
inhibit
assay
perform
whole
virion
na
titer
establish
dilut
pb
viral
stock
chosen
experi
aliquot
spot
onto
steril
glass
slide
mm
let
dri
air
insid
biosafeti
cabinet
min
viru
dri
expos
salin
sinc
ph
chang
treatment
may
interfer
enzymat
assay
glass
slide
treat
flow
lm
ppm
gno
min
exposur
chamber
describ
control
treat
air
condit
follow
ga
exposur
sampl
reconstitut
reaction
buffer
na
inhibit
assess
chemilumin
cent
neuraminida
e
activ
inhibit
assay
conduct
use
commerc
ialli
avail
kit
amplex
red
invitrogen
paisley
uk
experi
repeat
time
valu
shown
repres
mean
triplic
analysi
data
exposur
experi
express
mean
valu
repetit
standard
deviat
sd
statist
analysi
data
obtain
experi
perform
use
oneway
analysi
varianc
anova
tukey
multipl
compari
test
valu
p
consid
statist
signific
data
analysi
graphica
l
present
done
use
commerci
statist
packag
graphpadpr
v
graphpad
softwar
inc
usa
mdck
cell
infect
virion
treat
either
ppm
gno
air
control
h
done
assess
whether
gno
would
effect
viral
replicatio
n
viabil
control
cell
confirm
mdck
cell
adher
plate
infect
could
visual
stain
found
sensit
gno
result
reduct
plaqu
form
h
treatment
fig
chang
control
observ
follow
h
treatment
post
infect
inhibit
achiev
h
fig
treat
influenza
b
infect
cell
h
ppm
gno
show
effect
viru
compar
control
fig
three
virus
suspend
salin
expos
ppm
concentr
ation
gno
differ
exposur
time
control
treat
air
period
time
viru
infectivit
measur
use
plaqu
assay
mdck
cell
gno
shown
time
dose
depend
effect
three
virus
shown
fig
expos
continuo
us
dose
ppm
result
reduct
abil
infect
hour
h
complet
inactiv
h
use
ppm
result
increas
viral
inactivati
min
complet
inactiv
hour
repeatin
g
experim
nt
fig
reveal
similar
result
littl
higher
suscept
use
ppm
treatment
caus
slight
reduct
viral
load
h
complet
inhibit
h
use
ppm
complet
inhibit
reach
min
treatment
influenza
b
show
similar
pattern
influenza
although
less
susceptibl
e
gno
fig
reduct
min
inhibit
h
use
ppm
lower
gno
concentr
use
similar
pattern
seen
seen
tabl
expos
solut
gno
nitrit
produc
ph
reduc
appear
correl
time
exposur
concentratio
n
gno
ph
reduc
rang
treatment
h
ppm
gno
h
ppm
longer
exposur
time
greater
gno
concentr
lower
ph
becam
higher
amount
nitrit
found
solut
correl
found
amount
nitrit
measur
expos
solut
percentag
viru
inhibit
gener
higher
nitrit
concentratio
n
lower
ph
higher
percentag
viral
inhibit
found
determin
whether
ph
nitrit
alon
respons
viral
inhibit
test
viral
viabil
min
salin
salin
mm
nitrit
salin
reduc
ph
chose
ph
sinc
rang
ph
chang
detect
hour
exposur
nitrit
alon
ph
alon
signific
effect
surviv
result
show
expos
salin
reduc
ph
caus
reduct
viral
load
follow
min
exposur
signific
p
chang
viral
count
ph
treatment
nitrit
treatment
compar
control
order
elimin
chang
surround
solut
ph
factor
virucid
effect
gno
virion
anoth
experi
done
test
effect
gno
dri
viru
previou
result
indic
log
decreas
viru
infect
due
dri
start
titer
pfu
viru
titer
reduc
pfu
dri
ga
exposur
gno
ppm
air
control
flow
dri
viru
min
lpm
result
show
viral
infect
treat
viru
reduc
pfu
treatment
pfu
control
compar
control
h
exposur
na
inhibit
gno
shown
order
clarifi
natur
reaction
control
potenti
ph
chang
occur
expos
pb
gno
dri
influenza
virion
onto
glass
slide
ga
exposur
control
sampl
expos
air
treatment
sampl
expos
ppm
gno
min
follow
ga
exposur
dri
virion
reconstitut
reaction
buffer
test
na
inhibit
use
na
assay
kit
shown
fig
inhibit
na
achiev
min
exposur
ppm
gno
inhibit
min
result
studi
demonstrat
e
gno
signific
time
dose
depend
effect
abil
influenza
b
virion
infect
replic
mdck
cell
interestingl
shown
virion
suspend
normal
salin
expos
gno
lose
abil
infect
mdck
cell
wherea
mdck
cell
first
infect
influenza
expos
gno
virucid
effect
gno
modest
similar
report
result
donor
influenza
despit
modest
virucid
effect
previous
report
complex
viral
bacteria
model
bovin
bovin
respiratori
diseas
reduc
symptom
diseas
thu
may
downstream
host
interact
regul
may
come
play
vitro
studi
antivir
effect
gno
studi
influenza
infect
consist
effect
shown
rimmelzwaan
et
al
use
organ
donor
snap
influenza
virus
abl
demonstr
releas
snap
inhibit
influenza
viru
earli
stage
viral
replic
correl
viral
rna
synthesi
studi
use
coxsacki
viru
demonstr
interrupt
viral
life
cycl
may
due
nomedi
snitrosi
lation
cystein
residu
inhibit
proteas
activ
proteas
harri
et
al
demonstrat
ed
sever
process
late
stage
viral
replicatio
n
includ
viral
dna
replic
viral
protein
synthesi
virion
matur
greatli
inhibit
ifninduc
vaccinia
viru
vitro
studi
util
chemic
donor
shown
inhibit
viral
replic
dna
rna
virus
suggest
inhibit
viral
protein
rna
synthesi
viral
replic
modifi
molecul
reductas
proteas
requir
replic
knowledg
first
time
direct
virucid
activ
gno
cell
free
virion
report
may
target
virion
ha
na
could
bind
disrupt
infect
process
howev
littl
known
antivir
mechani
act
one
plausibl
mechan
antimicrobi
activ
involv
interactio
n
free
radic
reactiv
nitrogen
intermedi
reactiv
oxygen
intermedi
hydrogen
peroxid
h
superoxid
form
varieti
antimicrobi
al
molecula
r
speci
colasanti
et
al
theoriz
nitric
oxid
may
abl
affect
surfac
protein
nitrosyla
tion
cystein
moieti
within
structur
could
alter
stoichiometri
interactio
n
sialic
acid
prevent
fusion
virion
epitheli
cell
membran
e
result
studi
seem
support
notion
influenza
virus
surfac
glycoprotein
ha
na
antigen
defin
particular
strain
influenza
variat
molecul
time
permit
viru
evad
human
immun
respons
therefor
necessit
formul
new
vaccin
year
ha
sialic
acid
receptorbind
ing
molecul
mediat
entri
viru
target
cell
wherea
na
cleav
cellularrec
ptor
sialic
acid
residu
newli
form
particl
attach
cleavag
releas
virus
invad
new
cell
like
na
inhibitor
without
function
na
infect
could
limit
one
round
replicatio
n
rare
enough
caus
diseas
preliminari
result
shown
first
time
demonstrat
e
test
whole
virion
na
activ
inhibit
gno
thu
na
inhibit
may
one
possibl
mechan
viral
inhibit
current
screen
wide
varieti
virus
gno
assess
less
suscept
gno
concurrentl
also
evalu
na
ha
inhibit
virus
togeth
hope
shed
light
antivir
mechan
caus
gno
demonstrat
e
correl
length
time
salin
media
suspend
virion
expos
gno
antivir
effect
regardl
gno
concentr
ation
ppm
antivir
effect
coincid
specif
rang
nitrit
concentratio
n
acid
ph
depend
nt
exposur
time
explain
fact
time
gno
diffus
salin
result
increas
nitrit
concentr
ation
ion
react
proton
water
produc
hno
result
drop
ph
result
ph
level
along
nitrit
concentr
within
rang
found
antifung
antibact
rial
studi
use
combinati
acid
nitrit
acidifi
nitrit
produc
ga
although
low
ph
level
antivir
effect
show
elimin
acidifi
liquid
milieu
still
achiev
reduc
cellular
infectivit
gno
treatment
case
show
reduc
infect
thu
provid
evid
target
virion
may
bind
prevent
cellular
infect
notion
support
result
na
assay
moreov
shown
ad
viru
either
mm
nitrit
neutral
ph
salin
reduc
ph
h
effect
viru
viabil
found
confirm
conclus
support
thought
antivir
compound
reaction
time
min
fig
na
inhibit
gno
dri
glass
slide
expos
ppm
gno
control
expos
air
na
inhibit
measur
use
commerci
avail
kit
present
percentag
control
follow
min
gno
exposur
studi
gno
shown
inhibit
na
activ
nitrosyl
surfac
protein
may
mechan
inhibit
may
chang
surfac
protein
structur
like
ha
na
virion
thu
caus
reduc
infect
investig
conclud
gno
antivir
effect
influenza
season
flu
pandem
flu
influenza
b
effect
dose
depend
nt
begin
occur
highest
rang
dosag
appli
approv
use
inhal
full
term
infant
ppm
dose
ppm
signific
virucid
antivir
effect
earli
infect
influenza
observ
howev
influenza
b
similarli
affect
infect
susceptibl
e
cell
free
environ
propos
mechan
action
viral
inhibit
influenza
na
inactiv
gno
futur
research
focu
expand
experiment
observ
test
antivir
effect
gno
surfac
protein
ha
na
inhibit
wide
varieti
virus
order
help
elucid
mechan
antivir
action
